Manuscripts and Publications

Filters: Author is Han, Meilan K  [Clear All Filters]
Publication
Anderson WH, Ha JWook, Couper DJ, O'Neal WK, R Barr G, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, M Drummond B et al..  2017.  Variability in objective and subjective measures affects baseline values in studies of patients with COPD.. PLoS One. 12(9):e0184606.
Putcha N, R Barr G, Han MK, Woodruff PG, Bleecker ER, Kanner RE, Martinez FJ, Smith BM, Tashkin DP, Bowler RP et al..  2016.  Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort.. Thorax. 71:411-420.
Garudadri S, Woodruff PG, Han MK, Curtis JL, R Barr G, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G et al..  2019.  Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS.. Chest. 155(5):908-917.
Hansel NN, Paulin LM, Amanda G, Roger P, Alexis NE, Fan V, Bleecker E, Bowler RP, Comellas AP, Dransfield MT et al..  2017.  Subpopulations and Intermediate Outcomes in COPD (SPIROMICS) Air Pollution Study Design. BJM Open Respiratory Research. 4(1)
Bin Cho H, Chae KJu, Jin GYong, Choi J, Lin CLong, Hoffman EA, Wenzel SE, Castro M, Fain SB, Jarjour NN et al..  2019.  Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers.. Korean J Radiol. 20(7):1236-1245.
Sieren JP, Newell JD, R Barr G, Bleecker ER, Burnette N, Carretta EE, Couper D, Goldin J, Guo J, Han MK et al..  2016.  SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs.. Am J Respir Crit Care Med. 194(7):794-806.
Putcha N, Puhan MA, M Drummond B, Han MK, Regan EA, Hanania NA, Martinez CH, Foreman M, Bhatt SP, Make B et al..  2014.  A simplified score to quantify comorbidity in COPD.. PLoS One. 9(12):e114438.
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, R Barr G, Comellas AP, Hansel NN, Cooper CB et al..  2019.  Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study.. Sci Rep. 9(1):11367.
J Wells M, Arenberg DA, Barjaktarevic I, Bhatt SP, Bowler RP, Christenson SA, Couper DJ, Dransfield MT, Han MK, Hoffman EA et al..  2019.  Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy.. Ann Am Thorac Soc. 16(4):439-446.
Burkes RM, Gassett AJ, Ceppe AS, Anderson W, O'Neal WK, Woodruff PG, Krishnan JA, R Barr G, Han MK, Martinez FJ et al..  2018.  Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort.. Ann Am Thorac Soc. 15(7):808-816.
Buhr RG, Barjaktarevic IZ, P Quibrera M, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN et al..  2022.  Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.. Am J Respir Crit Care Med. 206(5):554-562.
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
Baugh AD, Shiboski S, Hansel NN, Ortega V, Barjaktarevic I, R Barr G, Bowler R, Comellas AP, Cooper CB, Couper D et al..  2022.  Reconsidering the Utility of Race-Specific Lung Function Prediction Equations.. Am J Respir Crit Care Med. 205(7):819-829.
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
Arjomandi M, Zeng S, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Cooper CB et al..  2019.  Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS.. Eur Respir J. 54(4)
Fawzy A, Woo H, Balasubramanian A, Barjaktarevic I, R Barr G, Bowler RP, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2021.  Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study.. Chronic Obstr Pulm Dis. 8(3):326-335.
Burkes RM, Ceppe AS, Couper DJ, Comellas AP, J Wells M, Peters SP, Criner GJ, Kanner RE, Paine R, Christenson SA et al..  2020.  Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Chronic Obstr Pulm Dis. 7(4):370-381.
Boes JL, Hoff BA, Bule M, Johnson TD, Rehemtulla A, Chamberlain R, Hoffman EA, Kazerooni EA, Martinez FJ, Han MK et al..  2015.  Parametric response mapping monitors temporal changes on lung CT scans in the subpopulations and intermediate outcome measures in COPD Study (SPIROMICS).. Acad Radiol. 22(2):186-94.
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D et al..  2020.  Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:1887-1898.
Zusman M, Gassett AJ, Kirwa K, R Barr G, Cooper CB, Han MK, Kanner RE, Koehler K, Ortega VE, Rd RPaine et al..  2021.  Modeling residential indoor concentrations of PM , NO , NO , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study.. Indoor Air. 31(3):702-716.
Morris MA, Jacobson SR, Kinney GL, Tashkin DP, Woodruff PG, Hoffman EA, Kanner RE, Cooper CB, M Drummond B, R Barr G et al..  2018.  Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Chronic Obstr Pulm Dis. 5(1):46-56.
Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP et al..  2021.  Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.. NPJ Biofilms Microbiomes. 7(1):14.
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, R Barr G, Comellas AP, Couper DJ et al..  2022.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 206(4):427-439.

Pages